SEARCH

SEARCH BY CITATION

References

  • Ackah AN, Coulibaly D, Digbeu H et al. (1995) Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Cote d'Ivoire. Lancet 345, 607610.
  • Aisu T, Raviglione MC, Van Praag E et al. (1995) Preventive chemotherapy for HIV-associated tuberculosis in Uganda: an operational assessment at a voluntary counselling and testing centre. AIDS 9, 267273.
  • American Thoracic Society (1983) Preventive therapy of tuberculosis infection. American Review of Respiratory Diseases 127, 790796.
  • Badri M, Wilson D & Wood R (2002) Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 359, 20592064.
  • Bucher HC, Griffith LE, Guyatt GH et al. (1999) Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. AIDS 13, 501507.
  • Casado JL, Moreno S, Fortun J et al. (2002) Risk factors for development of tuberculosis after isoniazid chemoprophylaxis in human immunodeficiency virus-infected patients. Clinical Infectious Diseases 34, 386389.
  • Chaisson RE, Schecter GF, Theuer CP et al. (1987) TB in patients with the acquired immunodeficiency syndrome. Clinical features, response to therapy, and survival. American Review of Respiratory Diseases 136, 570574.
  • Churchyard GJ, Fielding K, Charalambous S et al. (2003) Efficacy of secondary isoniazid preventive therapy among HIV-infected Southern Africans: time to change policy? AIDS 17, 20632070.
  • Colebunders R & Bastian I (2000) A review of the diagnosis and treatment of smear-negative pulmonary tuberculosis. The International Journal of Tuberculosis and Lung Disease 4, 97107.
  • Comstock GW, Baum C & Snider DE Jr (1979) Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies. American Review of Respiratory Diseases 119, 827830.
  • Connolly C, Reid A, Davies G et al. (1999) Relapse and mortality among HIV-infected and uninfected patients with tuberculosis successfully treated with twice weekly directly observed therapy in rural South Africa. AIDS 13, 15431547.
  • Corbett EL, Currie C, Churchyard GJ & Williams BG (2002) Strategies for reducing the burden of TB infection and disease in high HIV prevalence populations: modelling the impact of active case finding, antiretrovirals and preventive therapy. XIV International AIDS Conference Barcelona, Spain. Abstract WeOrC1312, p. 94.
  • Davies PDO (1998a) Clinical tuberculosis: chapter 21: preventive Therapy. In: Clinical Tuberculosis, 2nd edn (ed. DaviesPDO) Chapman & Hall, London, pp. 397416.
  • Davies PDO (1998b) Clinical tuberculosis: chapter 8: histopathology. In: Clinical Tuberculosis. Chapman & Hall, London.
  • Fitzgerald DW, Severe P, Joseph P et al. (2001) No effect of isoniazid prophylaxis for purified protein derivative-negative HIV-infected adults living in a country with endemic tuberculosis: results of a randomized trial. Journal of Acquired Immune Deficiency Syndromes 28, 305307.
  • Foudraine NA, Hovenkamp E, Notermans DW et al. (1999) Immunopathology as a result of highly active antiretroviral therapy in HIV-1-infected patients. AIDS 13, 177184.
  • Godfrey-Faussett P & Ayles H (2003) Can we control tuberculosis in high HIV prevalence settings? Tuberculosis (Edinburgh) 83, 6876.
  • Godfrey-Faussett P, Maher D, Mukadi YD et al. (2002) How human immunodeficiency virus voluntary testing can contribute to tuberculosis control. Bulletin of The World Health Organization 80, 939945.
  • Gordin FM, Cohn DL, Matts JP, Chaisson RE & O'Brien RJ (2004) Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons? Clinical Infectious Diseases 39, 561565.
  • Guelar A, Gatell JM, Verdejo J et al. (1993) A prospective study of the risk of tuberculosis among HIV-infected patients. AIDS 7, 13451349.
  • Halsey NA, Coberly JS, Desormeaux J et al. (1998) Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet 351, 786792.
  • Houk VN, Kent DC, Sorensen K & Baker JH (1968) The eradication of tuberculosis infection by isoniazid chemoprophylaxis. Archives of Environmental Health 16, 4650.
  • Johnson JL, Okwera A, Hom DL et al. (2001) Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults. AIDS 15, 21372147.
  • Kapp C (2004) Antiretrovirals give new hope and new life to South Africans. The long-awaited antiretroviral roll-out improves morale; at last there is hope for HIV/AIDS patients. Lancet 363, 1710.
  • Lambert ML, Hasker E, Van Deun A et al. (2003) Recurrence in tuberculosis: relapse or reinfection? The Lancet Infectious Diseases 3, 282287.
  • Lucas SB (1988) Mycobacteria and the tissues of man. In: The Biology of the Mycobacteria. Academic Press, London, pp. 107176.
  • Mocroft A, Vella S, Benfield TL et al. (1998) Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 352, 17251730.
  • Narita M, Ashkin D, Hollender ES & Pitchenik AE (1998) Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. American Journal of Respiratory and Critical Care Medicine 158, 157161.
  • Navas E, Martin-Davila P, Moreno L et al. (2002) Paradoxical reactions of tuberculosis in patients with the acquired immunodeficiency syndrome who are treated with highly active antiretroviral therapy. Archives of Internal Medicine 162, 9799.
  • Rodrigues LC & Smith PG (1990) Tuberculosis in developing countries and methods for its control. Transactions of the Royal Society of Tropical Medicine and Hygiene 84, 739744.
  • Saukkonen J (2004) Rifampin and pyrazinamide for latent tuberculosis infection: clinical trials and general practice. Clinical Infectious Diseases 39, 566568.
  • Selwyn PA, Hartel D, Lewis VA et al. (1989) A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. The New England Journal of Medicine 320, 545550.
  • Sonnenberg P, Murray J, Glynn JR et al. (2001) HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 358, 16871693.
  • Wendel KA, Alwood KS, Gachuhi R et al. (2001) Paradoxical worsening of tuberculosis in HIV-infected persons. Chest 120, 193197.
  • WHO Report on the Tuberculosis Epidemic (1994) TB – A Global Emergency, Low Priority. WHO, Geneva.
  • WHO Global Tuberculosis Programme & UNAIDS (1998) Policy Statement on Preventive Therapy Against Tuberculosis in People Living with HIV. WHO, Geneva. Document WHO/TB/98.255; UNAIDS/98.34.
  • Wilkinson D, Squire SB & Garner P (1998) Effect of preventive treatment for TB in adults infected with HIV: systematic review of randomised placebo controlled trials. British Medical Journal 317, 625629.
  • Woldehanna S & Volmink J (2004) Treatment of latent tuberculosis infection in HIV infected persons. The Cochrane Database of Systematic Reviews (1): CD000171. Review.